Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Non-Current Assets for 16 consecutive years, with $23.9 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 52.12% year-over-year to $23.9 million; the TTM value through Dec 2025 reached $164.7 million, down 23.86%, while the annual FY2025 figure was $23.9 million, 52.12% down from the prior year.
  • Non-Current Assets hit $23.9 million in Q4 2025 for Sangamo Therapeutics, down from $44.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $325.0 million in Q3 2021 and bottomed at $23.9 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $160.5 million, with a median of $118.8 million recorded in 2023.
  • Year-over-year, Non-Current Assets skyrocketed 30.68% in 2021 and then crashed 72.92% in 2023.
  • Sangamo Therapeutics' Non-Current Assets stood at $323.2 million in 2021, then fell by 18.87% to $262.2 million in 2022, then plummeted by 72.92% to $71.0 million in 2023, then dropped by 29.65% to $49.9 million in 2024, then tumbled by 52.12% to $23.9 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $23.9 million, $44.6 million, and $47.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.